-

09:57:12 PM

LLY Stock News

LLY - Lilly(Eli) & Co

06/29/22 6:45 AM

NYSE : LLY

covid-19

Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options

Eli Lilly and Company (NYSE: LLY) today announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of

RHEA-AI

negative

06/27/22 1:26 PM

NYSE : LLY

dividends

Lilly Declares Third-Quarter 2022 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common stock.The dividend is payable on Sept. 9, 2022 to shareholders of record at the close of business

RHEA-AI

neutral

06/13/22 9:50 PM

NYSE, Nasdaq : LLY, INCY

fda approval

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT ® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia

RHEA-AI

neutral

06/07/22 12:01 AM

NYSE : LLY

Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials

80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observedData supported both once every two week and once every four week maintenance dosing, with consistent and durable responsesINDIANAPOLIS , June

RHEA-AI

positive

06/06/22 7:00 PM

NYSE : LLY

New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®

Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action studyExploratory analysis showed that Mounjaro achieved A1C and weight targets in less time than injectable semaglutide 1 mg or

RHEA-AI

positive

06/05/22 4:30 PM

NYSE : LLY

Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study

Jardiance showed a reduction in relative risk of all-cause mortality by 40% compared with DPP-4 inhibitors in the subset of people with Medicare coverage Data from these final analyses of EMPRISE complements findings from the landmark EMPA-REG OUTCOME ® trial RIDGEFIELD, Conn. and INDIANAPOLIS ,

RHEA-AI

neutral

06/04/22 11:00 AM

NYSE : LLY

Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo

RHEA-AI

neutral

06/04/22 10:02 AM

NYSE : LLY

Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3

RHEA-AI

neutral

06/03/22 10:00 AM

NYSE : LLY

conferences

Lilly to Participate in Goldman Sachs Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. Anne White, senior vice president and president, Lilly Neuroscience, and Mark Mintun, senior vice president, research and

RHEA-AI

neutral

05/26/22 5:00 PM

NYSE : LLY

Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Eli Lilly and Company (NYSE: LLY) today announced that data from its oncology portfolio will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022. The data include new analyses from studies of

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

LLY Data

Websitewww.lilly.com
CeoDavid Ricks
Security nameLilly(Eli) & Co
Issue typecs
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressLilly Corporate Ctr
StateIndiana
CityIndianapolis
Zip46285-0001
CountryUS
Phone13172762000

About Lilly(Eli) & Co

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.